For Treatment of Type II Diabetes and Its Complications
In vitro studies of a drug developed by scientists from the Urals Federal University and Institute of Organic Synthesis, Urals Department RAS have been completed. The new compound is intended for prevention and treatment of type II diabetes complications.
The studies at laboratories of Volgograd State Medical University have shown that the substance developed by chemists from Urals is not toxic and active at low concentrations.
When results of studies are analyzed preparations for preclinical studies at the VolgSMU will begin.
Head of Pharmacology Department at VolSMU professor Alexander Spasov, who recently visited Urals Pharmaceutical University, remarks that selection of molecules for further preclinical study has already begun. It is important to work out regulations on substances, pharmaceutical form, study pharmacology, toxicology, prepare the whole kit of documents for clinical studies. Besides sugar lowering therapy it is important to perform antiglycating therapy, i.e. add a glucose toxicity lowering tablet. Hypoglycaemic drugs and diet may lower blood sugar, however, these interventions do not inhibit destructive processes, and the process of non-fermentative changes of protein molecules continues. The molecule we develop should interrupt the process and make sugar lowering therapy more effective.